Slide 1: Coloplast Earnings Conference Call FY 2017/18
Coloplast Earnings Conference Call FY 2017/18 1 November 2018
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast delivered 8% organic growth for the sixth consecutive quarter and 8% organic growth for 2017/18
Coloplast delivered 8% organic growth for the sixth consecutive quarter and 8% organic growth for 2017/18 2017/18 Highlights • CEO Lars Rasmussen steps down and Board of Directors appoints Revenue growth Kristian Villumsen as new CEO Reported revenue (DKKm) +8% • Full year organic growth of 8% (6% r
Slide 4: 8% organic growth in 2017/18 driven by strong performance across business vs. market growth of 4-5%
8% organic growth in 2017/18 driven by strong performance across business vs. market growth of 4-5% FY 17/18 revenue by business area FY 17/18 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth a
Slide 5: FY 17/18 reported revenue driven by strong organic growth of 8% but significantly impacted by FX headwinds
FY 17/18 reported revenue driven by strong organic growth of 8% but significantly impacted by FX headwinds Comments Revenue development • FY 2017/18 reported revenue increased by DKK 921m or (DKKm) 185 6% compared to FY 2016/17 -463 16,449 • The majority of growth was driven by organic growth 1,229
Slide 6: FY 2017/18 EBIT margin of 31% impacted by commercial investments and restructuring costs
FY 2017/18 EBIT margin of 31% impacted by commercial investments and restructuring costs Comments EBIT margin development (%) • EBIT increased 1% to DKK 5,091m with a reported margin of 31% (31% in constant currencies) compared to 32% last year 32.4 • Gross margin of 67% in DKK compared to 68% same
Slide 7: Organic growth guidance for FY 2018/19
Organic growth guidance for FY 2018/19 Guidance 2018/19 Guidance 2018/19 (DKK)* Key assumptions • Up to 1% negative price pressure ~8% 8-9% • DKK guidance includes growth from Lilial and IncoCare Sales growth (organic) • Incremental investments of up to 2% of revenue • Restructuring costs of DKK 25m
Slide 8: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C